Eledon Pharmaceuticals to Present New Long-Term Data from Phase 2 BESTOW Trial of Tegoprubart for the Prevention of Rejection in Kidney Transplantation at American Transplant Congress
Eledon Pharmaceuticals announced it will present updated and new long-term clinical data from its Phase 2 BESTOW trial and extension study of tegoprubart, an anti-CD40L antibody, aimed at preventing kidney transplant rejection. Presentations will occur at the American Transplant Congress in June 2026, accompanied by a conference call to discuss res…